BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Aims to Commercialize AI-Driven Predictive Model of Ovarian Cancer in Q1 2020
Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, recently issued an update regarding its groundbreaking CancerQuest 2020 initiative driven by its Helomics subsidiary (http://nnw.fm/y6fnc). Per the update, the company intends to have its first predictive model of ovarian cancer prepared for initial commercialization in the first quarter of 2020. An article discussing the company reads, “‘We believe that this effort will enhance our understanding of the molecular profiles of women with ovarian cancer by using the power of artificial intelligence to create predictive…